Raymond James Maintains Strong Buy on Vera Therapeutics, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Vera Therapeutics (NASDAQ:VERA) and increased the price target from $57 to $68.
May 10, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James' analyst Steven Seedhouse has reaffirmed a Strong Buy rating on Vera Therapeutics and raised the price target from $57 to $68, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong conviction in the company's future performance. This endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100